Palbociclib exposure in relation to efficacy and toxicity in patients with advanced breast cancer
The absence of an association between palbociclib exposure and PFS and the presence of the association between palbociclib exposure and dose reductions suggest that dose reductions may safely be carried out in case of palbociclib-related toxicity.
Authors
- Alwin D. R. Huitema (ORCID: https://orcid.org/0000-0003-1939-4639)
- A. Jager
- Esther Oomen‐de Hoop (ORCID: https://orcid.org/0000-0003-2506-3852)
- Gabe S. Sonke (ORCID: https://orcid.org/0000-0001-8088-9628)
- Inge R. Konings (ORCID: https://orcid.org/0000-0002-9574-4023)
- Neeltje Steeghs (ORCID: https://orcid.org/0000-0003-2989-2279)
- Hinke Siebinga (ORCID: https://orcid.org/0000-0001-7767-0393)
- Stijn L.W. Koolen (ORCID: https://orcid.org/0000-0002-0973-7530)
- Ron H.J. Mathijssen (ORCID: https://orcid.org/0000-0001-5667-5697)
- C. Louwrens Braal (ORCID: https://orcid.org/0000-0003-3600-9851)
- Sanne M. Buijs (ORCID: https://orcid.org/0000-0003-0548-1803)
- Ma Ida Mohmaed Ali (ORCID: https://orcid.org/0000-0002-6853-6763)
- Annemiek van Ommen‐Nijhof (ORCID: https://orcid.org/0000-0002-1797-1060)
- Noor Wortelboer (ORCID: https://orcid.org/0009-0006-1649-748X)
Institutions
- The Netherlands Cancer Institute (NL)
- Oncode Institute (NL)
- Princess Máxima Center (NL)
- Erasmus MC Cancer Institute (NL)
- Cancer Center Amsterdam (NL)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-02-15
- DOI
- https://doi.org/10.1016/j.esmoop.2025.104290
- Citations
- 2
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- ZonMw